Gonadorelin vs Tesamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Gonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profileTesamorelin
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.
Full profile| Gonadorelin | Tesamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse | Egrifta, Egrifta SV, TH9507, GHRH analog |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 50mcg–200mcg mcg, 2–3x per week subcutaneous | 1.28mg–2mg mg, once daily (subcutaneous) |
| Administration | Subcutaneous injection, Intranasal (pulsatile delivery) | Subcutaneous injection (abdomen, with site rotation) |
| Key side effects | Injection site reactions, Headache, Nausea, Flushing | Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia |
| Cited sources | 2 references | 5 references |
Key differences
- Evidence level differs: Gonadorelin is research-stage, while Tesamorelin is fda-approved.
- Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
- Dosing units differ: Gonadorelin is dosed in mcg, Tesamorelin in mg — they operate at different scales.
- Frequency: Gonadorelin is typically 2–3x per week subcutaneous; Tesamorelin is once daily (subcutaneous).
- Research depth: this profile cites 2 sources for Gonadorelin vs 5 for Tesamorelin.
How each works
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
Tesamorelin
Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.